Showing results (921-930 of 928) with videos related to
Sort By:
Pageof 93
You have reached the last page of results.This site can display upto 928 results.
The Lancet. Diabetes & Endocrinology|November 22, 2025
Trajectories of type 2 diabetes and cancer in 330 000 individuals with prediabetes: 20-year observational study in EnglandFrancesco Zaccardi, Suping Ling, Clare Gillies, et al.The Lancet. Diabetes & Endocrinology|May 2, 2024
Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trialChristian L Roth, Cecilia Scimia, Ashley H Shoemaker, et al.The Lancet. Diabetes & Endocrinology|April 25, 2024
Food additive emulsifiers and the risk of type 2 diabetes: analysis of data from the NutriNet-Santé prospective cohort studyClara Salame, Guillaume Javaux, Laury Sellem, et al.The Lancet. Diabetes & Endocrinology|December 24, 2023
Daily low-dose aspirin and incident type 2 diabetes in community-dwelling healthy older adults: a post-hoc analysis of efficacy and safety in the ASPREE randomised placebo-controlled trialSophia Zoungas, Zhen Zhou, Alice J Owen, et al.The Lancet. Diabetes & Endocrinology|July 30, 2026
Type 1 diabetes in older populationsAnna R Kahkoska, Peter K Yang, Joshua J Neumiller, et al.The Lancet. Diabetes & Endocrinology|August 10, 2026
Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trialLixin Guo, Xiaolei Bao, Kuo-Chin Huang, et al.The Lancet. Diabetes & Endocrinology|August 21, 2026
Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trialStanley H Hsia, Harold E Bays, Liana K Billings, et al.The Lancet. Diabetes & Endocrinology|August 27, 2026
From adiposity to multisystem morbidity: the case for weight loss as disease modificationNaveed Sattar, Lyn D Ferguson, Matthew M Y LeePageof 93